Company intelligence / Profile preview

ICOS Corporation

Bothell, Washington, USpdf.secdatabase.com ↗

Ownership: Private
Employees: ~700
Development stage: Commercial

Overview

Developed tadalafil (Cialis) for erectile dysfunction. Had multiple clinical-stage candidates including IC14 monoclonal antibody and sepsis treatments before acquisition.

Therapeutic areas: Men's HealthPulmonologyCardiovascularInfectious Diseases
Modalities: Small moleculesMonoclonal antibodies
Industry: Biotech

Drug pipeline

1 asset

tadalafil

Commercial

Indications: Erectile dysfunction, Benign prostatic hyperplasia, Pulmonary arterial hypertension, pulmonary arterial hypertension (PAH, WHO group 1)

Partnerships

Eli Lilly (Cialis joint venture 1998-2007)GlaxoSmithKline (early collaboration)Seattle Genetics (antibody manufacturing)

Beyond the preview

Go deeper on ICOS Corporation.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ICOS Corporation.

Explore the full profile